Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500123
Status:
RECRUITING
Last Update Posted:
2023-08-29
First Post:
2007-07-11
Brief Title:
The Alpha-1 Foundations and University of Floridas Alpha-1 Coded Testing ACT Study
Sponsor:
University of Florida
Organization:
University of Florida
Study Overview
Official Title:
The Alpha-1 Foundations and University of Floridas Alpha-1 Coded Testing ACT Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACT
Brief Summary:
The Alpha-1 Coded Testing ACT Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency
Detailed Description:
Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications All genetic tests have risks and possible benefits The ACT study evaluates the population demographics reasons for testing and outcomes through a confidential testing program Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are being investigated Concerns about genetic confidentiality are lessened in this study by a coded testing procedure that returns results through the mail to study participants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None